In development for atopic dermatitis.
ARQ-234 is a fusion protein that serves as an agonist with high selectivity and potency for the CD200 receptor (CD200R).
ARQ-234 is a CD200R agonist under investigation for the treatment of atopic dermatitis.
Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd. News release. Arcutis Biotherapeutics, Inc; September 7, 2022.